Mode
Text Size
Log in / Sign up
N/A N=89 Randomized Diagnostic

SMBG Protocols Predicting Glucose Levels in Senior Diabetes Mellitus With CAD

Diabetes Mellitus, Type 2 · Coronary Artery Disease

Enrolled (actual)
89
Serious AEs
20.2%
Results posted
Jul 2017
Primary outcome: Primary: Evaluation of Peak and Nadir Glucose Profiles From Continuous Glucose Monitoring System (CGMS) — 8.86; 8.72; 8.80; 6.87 mmol/L

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
SMBG (Behavioral); CGMS (Other)
Age
Older Adult · 65+ yrs
Sex
All
Sponsor
Beijing Anzhen Hospital
Primary completion
Jun 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Evaluation of Peak and Nadir Glucose Profiles From Continuous Glucose Monitoring System (CGMS)
8.86; 8.72; 8.80; 6.87; 6.05; 6.15
SECONDARY
The Correlation Study Between HbA1c and Glycemic Profiles of MBG (Mean Blood Glucose) From SMBG Protocols and CGMS
7.92; 8.00; 7.81; 7.62; 7.24; 7.76 <0.001 sig
SECONDARY
Number of Participants With Severe Hypoglycemia (≤50 mg/dL or 2.8mmol/L),Captured by SMBG Method and CGMS
4; 3; 7; 3; 1; 3
SECONDARY
HbA1c(%) at Endpoint
6.9; 6.7; 6.6

Summary

Self-monitoring of blood glucose (SMBG) is a common way to assess glycemic control in diabetes management. Multiple times of blood glucose measurements by fingerstick in the same day are of tough challenge to it. The changes and variations of glucose excursion in senior diabetics with Coronary Artery Disease (CAD)involve a safety issue besides glycated hemoglobin (GHb) value. The goal of this study is to explore modified SMBG protocols for precisely monitoring and predicting glycemic excursion, variability in senior type 2 diabetics with CAD.

Eligibility Criteria

Inclusion Criteria

  • Clinical diagnosis of type 2 diabetes
  • Clinical diagnosis of coronary artery disease
  • Age ≥65 years
  • The blood glucose is controlled by diets and (or) oral hypoglycemic drugs
  • BMI≤28 kg/m²
  • Being able to monitor and record capillary glucose value by themselves at home

Exclusion Criteria

  • Diabetic ketoacidosis (DKA)
  • Acute cardiovascular events
  • Anemia
  • Insulin treatment
  • Incapable to perform SMBG at home
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01954771). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search